Checkpoint CD24 function on tumor and immunotherapy
CD24 is a protein found on the surface of cells that plays a crucial role in the proliferation, invasion, and spread of cancer cells. It adheres to cell membranes through glycosylphosphatidylinositol (GPI) and is associated with the prognosis and survival rate of cancer patients. CD24 interacts with...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2024-02-01
|
| Series: | Frontiers in Immunology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fimmu.2024.1367959/full |
| _version_ | 1797291814058721280 |
|---|---|
| author | Shiming Huang Shiming Huang Shiming Huang Xiaobo Zhang Yingtian Wei Yueyong Xiao |
| author_facet | Shiming Huang Shiming Huang Shiming Huang Xiaobo Zhang Yingtian Wei Yueyong Xiao |
| author_sort | Shiming Huang |
| collection | DOAJ |
| description | CD24 is a protein found on the surface of cells that plays a crucial role in the proliferation, invasion, and spread of cancer cells. It adheres to cell membranes through glycosylphosphatidylinositol (GPI) and is associated with the prognosis and survival rate of cancer patients. CD24 interacts with the inhibitory receptor Siglec-10 that is present on immune cells like natural killer cells and macrophages, leading to the inhibition of natural killer cell cytotoxicity and macrophage-mediated phagocytosis. This interaction helps tumor cells escape immune detection and attack. Although the use of CD24 as a immune checkpoint receptor target for cancer immunotherapy is still in its early stages, clinical trials have shown promising results. Monoclonal antibodies targeting CD24 have been found to be well-tolerated and safe. Other preclinical studies are exploring the use of chimeric antigen receptor (CAR) T cells, antibody-drug conjugates, and gene therapy to target CD24 and enhance the immune response against tumors. In summary, this review focuses on the role of CD24 in the immune system and provides evidence for CD24 as a promising immune checkpoint for cancer immunotherapy. |
| first_indexed | 2024-03-07T19:43:10Z |
| format | Article |
| id | doaj.art-1ef781d34f48485bb3c6c409af1bcb12 |
| institution | Directory Open Access Journal |
| issn | 1664-3224 |
| language | English |
| last_indexed | 2024-03-07T19:43:10Z |
| publishDate | 2024-02-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Immunology |
| spelling | doaj.art-1ef781d34f48485bb3c6c409af1bcb122024-02-29T05:17:06ZengFrontiers Media S.A.Frontiers in Immunology1664-32242024-02-011510.3389/fimmu.2024.13679591367959Checkpoint CD24 function on tumor and immunotherapyShiming Huang0Shiming Huang1Shiming Huang2Xiaobo Zhang3Yingtian Wei4Yueyong Xiao5Department of Radiology, First Medical Center, Chinese People’s Liberation Army General Hospital, Beijing, ChinaGraduate School, Chinese PLA Medical School, Beijing, ChinaDepartment of Nuclear Medicine, Characteristic Medical Center of the Chinese People’s Armed Police Force, Tianjin, ChinaDepartment of Radiology, First Medical Center, Chinese People’s Liberation Army General Hospital, Beijing, ChinaDepartment of Radiology, First Medical Center, Chinese People’s Liberation Army General Hospital, Beijing, ChinaDepartment of Radiology, First Medical Center, Chinese People’s Liberation Army General Hospital, Beijing, ChinaCD24 is a protein found on the surface of cells that plays a crucial role in the proliferation, invasion, and spread of cancer cells. It adheres to cell membranes through glycosylphosphatidylinositol (GPI) and is associated with the prognosis and survival rate of cancer patients. CD24 interacts with the inhibitory receptor Siglec-10 that is present on immune cells like natural killer cells and macrophages, leading to the inhibition of natural killer cell cytotoxicity and macrophage-mediated phagocytosis. This interaction helps tumor cells escape immune detection and attack. Although the use of CD24 as a immune checkpoint receptor target for cancer immunotherapy is still in its early stages, clinical trials have shown promising results. Monoclonal antibodies targeting CD24 have been found to be well-tolerated and safe. Other preclinical studies are exploring the use of chimeric antigen receptor (CAR) T cells, antibody-drug conjugates, and gene therapy to target CD24 and enhance the immune response against tumors. In summary, this review focuses on the role of CD24 in the immune system and provides evidence for CD24 as a promising immune checkpoint for cancer immunotherapy.https://www.frontiersin.org/articles/10.3389/fimmu.2024.1367959/fullCD24immunotherapymacrophageSiglec-10antibody |
| spellingShingle | Shiming Huang Shiming Huang Shiming Huang Xiaobo Zhang Yingtian Wei Yueyong Xiao Checkpoint CD24 function on tumor and immunotherapy Frontiers in Immunology CD24 immunotherapy macrophage Siglec-10 antibody |
| title | Checkpoint CD24 function on tumor and immunotherapy |
| title_full | Checkpoint CD24 function on tumor and immunotherapy |
| title_fullStr | Checkpoint CD24 function on tumor and immunotherapy |
| title_full_unstemmed | Checkpoint CD24 function on tumor and immunotherapy |
| title_short | Checkpoint CD24 function on tumor and immunotherapy |
| title_sort | checkpoint cd24 function on tumor and immunotherapy |
| topic | CD24 immunotherapy macrophage Siglec-10 antibody |
| url | https://www.frontiersin.org/articles/10.3389/fimmu.2024.1367959/full |
| work_keys_str_mv | AT shiminghuang checkpointcd24functionontumorandimmunotherapy AT shiminghuang checkpointcd24functionontumorandimmunotherapy AT shiminghuang checkpointcd24functionontumorandimmunotherapy AT xiaobozhang checkpointcd24functionontumorandimmunotherapy AT yingtianwei checkpointcd24functionontumorandimmunotherapy AT yueyongxiao checkpointcd24functionontumorandimmunotherapy |